Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

Por Paraiso, K H T, Fedorenko, I V, Cantini, L P, Munko, A C, Hall, M, Sondak, V K, Messina, J L, Flaherty, K T, Smalley, K S M
Publicado em 2010

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

Por Algazi, A P, Weber, J S, Andrews, S C, Urbas, P, Munster, P N, DeConti, R C, Hwang, J, Sondak, V K, Messina, J L, McCalmont, T, Daud, A I
Publicado em 2012

Genetic variations of the EVER genes, cutaneous human papillomavirus (HPV) infection, and squamous cell carcinoma of the skin

Por Hampras, S.S., Rollison, D.E., Tommasino, M., Gheit, T., Schabath, M.B., Messina, J.L., Fenske, N.A., Cherpelis, B.S., Sondak, V.K., Iannacone, M.R., Schmitt, M., Pawlita, M.
Publicado no Br J Dermatol (2015)

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

Por Tetzlaff, M T, Messina, J L, Stein, J E, Xu, X, Amaria, R N, Blank, C U, van de Wiel, B A, Ferguson, P M, Rawson, R V, Ross, M I, Spillane, A J, Gershenwald, J E, Saw, R P M, van Akkooi, A C J, van Houdt, W J, Mitchell, T C, Menzies, A M, Long, G V, Wargo, J A, Davies, M A, Prieto, V G, Taube, J M, Scolyer, R A
Publicado no Ann Oncol (2018)